The health and safety of our patients and teammates is our top priority. We are keeping a close eye on this situation and reinforcing the extensive infection control practices already in place to protect them. Click here to find videos and additional resources.
Phosphorus Binder News
This week Genzyme Corp. announced their phosphorus binding drug Renagel® is being replaced by the newer binder Renvela® in the US. The newer drug, available since March 2008, is similar to Renagel® but with the added benefit of a carbonate buffer. Renvela® contains no calcium or metals, and is not absorbed as it passes through the GI tract. It has less impact on bicarbonate levels and fewer GI side effects compared to Renagel®.
The transition is expected to be completed by September 2009.
Genzyme is also working on a powdered form of Renvela®, expected to be available later this year.
Phosphorus binders are medications that bind phosphorus in the gastrointestinal (GI) tract to help reduce absorption into the blood. Binders along with a low phosphorus diet help dialysis patients maintain normal phosphorus levels. Uncontrolled phosphorus can cause heart and bone problems in people with kidney disease.
Looking for low phosphorus menus and recipes? DaVita Diet Helper has just what you need.